USFDA classifies inspection of Lupin's Goa facility as OAI

27 May 2019 Evaluate

USFDA has classified the inspection conducted at Lupin’s Goa facility from January 28 to February 8, 2019 as Official Action Indicated (OAI). The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed. The inspection at the Goa facility had closed with two observations. Based on USFDA's Concept of Operations program, the Company understands that the status of the facility is still under review.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.80 -12.95 (-0.59%)
13-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.80
Dr. Reddys Lab 1190.35
Cipla 1447.60
Zydus Lifesciences 900.25
Lupin 2176.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×